 Patients undergo bone marrow and blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for minimal residual disease and T-cell subsets i.e., CD4 and CD8 via quantitative-PCR analysis and flow cytometry and cytomegalovirus antigens via PCR. 